Pathology Department, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):251-4. doi: 10.1177/1074248411407070.
Ischemic preconditioning (IP) is the most effective, reproducible form of protection against myocardial cell death yet described. The mechanism of classic IP has not been identified, but recent investigations have focused on the mitochondrial permeability transition pore (mPTP). Similarly, the mechanism of the "second window of protection" (SWOP) is not known but thought to involve increased expression of important gene products. Currently, IP in the clinical arena is limited to cardiac surgery, planned angioplasty, and organ preservation protocols. To move preconditioning into a broader clinical arena will require resolution of important fundamental yet stubborn problems involving both basic and clinical science. Important unresolved issues include the mechanisms involved in the transition from reversible to irreversible injury, the amount of potential salvageable myocardium present at the onset of reperfusion, the identity and signaling of the mPTP, the optimization of protocols, the identity of end effectors (SWOP), and the identification of the best experimental model systems. From a clinical standpoint, important issues include the influence of comorbidities on cardioprotection, identification of appropriate animal models, the lack of a biologic marker of the cardioprotective state, the influence of coexistent therapeutic drugs, potential toxicity of pharmacologic mimics, and the window of opportunity for significant protection. Ischemic preconditioning has yielded promising results in other organs including the brain as well as tissue preservation for certain surgical procedures that will require definition of the underlying mechanism(s) to be fully exploited clinically. Over the past 25 years, the scientific community has learned much regarding the biology and potential mechanisms of IP and the concept has been expanded to many other organ systems in many other clinically relevant scenarios. To realize the full clinical potential will require continued investigation into the mechanism.
缺血预处理(IP)是迄今为止描述的最有效、可重复的心肌细胞死亡保护形式。经典 IP 的机制尚未确定,但最近的研究集中在线粒体通透性转换孔(mPTP)上。同样,“第二保护窗口”(SWOP)的机制尚不清楚,但被认为涉及重要基因产物表达的增加。目前,IP 在临床领域仅限于心脏手术、计划进行的血管成形术和器官保存方案。要将预处理推向更广泛的临床领域,需要解决涉及基础科学和临床科学的重要而顽固的问题。重要的未解决问题包括从可逆损伤向不可逆损伤转变所涉及的机制、再灌注时存在的潜在可挽救心肌量、mPTP 的身份和信号转导、方案的优化、终效器的身份(SWOP),以及确定最佳实验模型系统。从临床角度来看,重要的问题包括合并症对心脏保护的影响、合适动物模型的确定、缺乏心脏保护状态的生物学标志物、共存治疗药物的影响、药理模拟物的潜在毒性以及具有重要保护作用的机会窗口。缺血预处理在其他器官(包括大脑)以及某些外科手术的组织保存中取得了有希望的结果,这需要确定潜在的机制,以便在临床上充分利用。在过去的 25 年中,科学界已经了解了很多关于 IP 的生物学和潜在机制的知识,并且该概念已经扩展到许多其他器官系统和许多其他临床相关场景中。要实现全部的临床潜力,需要继续研究其机制。